Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
12/2005
12/08/2005US20050272077 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
12/08/2005US20050271688 Modified vaccinia ankara virus variant
12/08/2005US20050271674 Methods and compositions for modulating the immune system of animals
12/08/2005US20050271654 Antibody purification
12/08/2005US20050271624 Use of apoptosis inducing agents in the treatment of (auto) immune diseases
12/08/2005DE19930557B4 Verfahren zur Herstellung von Hydraten von Ciprofloxacin und von Ciprofloxacin-Anhydrat enthaltenden pharmazeutischen Zusammensetzungen Process for the preparation of hydrates of ciprofloxacin and of ciprofloxacin containing pharmaceutical compositions anhydrate
12/08/2005CA2822895A1 Influenza hemagglutinin and neuraminidase variants
12/08/2005CA2568014A1 Lactic acid bacteria with immunoregulating activities
12/08/2005CA2568009A1 Use of ppar agonists to treat ruminants
12/08/2005CA2567959A1 Pharmaceutical products for treating neoplastic disease and inflammation
12/08/2005CA2567637A1 Using organic and/or inorganic potassium and its salts to treat autoimmune and other health disorders and methods of administering the same
12/08/2005CA2567398A1 New use
12/08/2005CA2565805A1 Msh-agonist tripeptide conjugates
12/07/2005EP1602666A1 Novel protein and its dna
12/07/2005EP1602660A1 Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators
12/07/2005EP1602658A1 Tricyclic pyrazole derivatives as cannabinoid receptor antagonists
12/07/2005EP1602656A1 Pyrazole derivatives having affinity for cb1 and/or cb2 receptors
12/07/2005EP1602655A1 Benzofuran derivative
12/07/2005EP1602377A1 Composition containing beta-glucan and constipation-relieving drug, immunopotentiator and skin moistening agent using the composition
12/07/2005EP1601767A2 USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF EIF-5A1
12/07/2005EP1601657A1 Pyrazole modulators of atp-binding cassette transporters
12/07/2005EP1601374A2 Compositions and methods for diagnosing and treating an inflammation
12/07/2005EP1601371A2 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components
12/07/2005EP1601355A2 Pharmaceutical preparations containing thiazolidinediones for the treatment or prevention of ip-10 mediated diseases
12/07/2005EP1601333A2 Novel insertion sites in pox vectors
12/07/2005EP1496917B1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
12/07/2005EP1385886B1 Method for preparing human immunoglobulin concentrates for therapeutic use
12/07/2005EP1379528A4 Pyrazolopyrimidines as therapeutic agents
12/07/2005EP1307449B1 1,4-dihydropyridines as bradykinin antagonists
12/07/2005EP1301191B1 Potent immunostimulants from microalgae
12/07/2005EP1294711B1 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
12/07/2005EP1252323B1 Virus strains for the oncolytic treatment of cancer
12/07/2005EP1247529B1 Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs
12/07/2005EP1246828B1 Benzosulfones with calcium antagonist activity
12/07/2005EP1196129B1 Pharmaceutical and cosmetic compositions comprising urocanic acid derivatives as radical scavengers or antioxidants
12/07/2005EP1171442B1 Xanthine derivatives and analogs as cell signalling inhibitors
12/07/2005EP1147089B1 Phenylphenanthridines with pde-iv inhibiting activity
12/07/2005EP0738328B1 Composition containing nucleic acids, preparation and uses
12/07/2005CN1705649A Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
12/07/2005CN1704469A Method for producing Chinese aweto fungus
12/07/2005CN1704404A Tricyclic protein kinase inhibitors
12/07/2005CN1230538C Immunological reagent specifically interreacting with the extracellular domain of the human zeta chain
12/07/2005CN1230439C Cisplatinun dinuclear platinum complex for treating cancer and its therapeutic method
12/07/2005CN1230434C Indazolyl-substituted pyrroline compounds as kinase inhibitor
12/07/2005CN1230433C Cyclic AMP-specific phosphodiesterase inhibitors
12/07/2005CN1230431C Arylmethylamine derivatives for use as tryptase inhibitors
12/07/2005CN1230421C Amide compounds and medicinal use thereof
12/07/2005CN1230165C Azolylcarbynol derivatives of aryl (or heteroaryl) for treatment of respiratory diseases
12/07/2005CN1230151C Non-invasive transdermal vaccination
12/07/2005CN1230150C Slow release pharmaceutical compositions comprising lithium carbonate
12/06/2005US6972296 Antichoelsterol agents; cardiovascular disorders; antihistamines; multiple sclerosis; antihistamines
12/06/2005US6972171 mixing polynucleotides with folic acid, hormones, peptides, glycoproteins, lipids or phosphatides to form nucleotides used as drugs; genetic engineering; gene expression
12/06/2005US6972128 allogeneic immunotherapy; vaccines; immortalization
12/06/2005CA2233975C Succinimide and maleimide cytokine inhibitors
12/06/2005CA2096528C Retroviral protease inhibitors
12/02/2005CA2509077A1 Water-based compositions comprising a polyethylene glycol-based solubilizing agent and a taxane useful in the treatment of coronary artery disease
12/01/2005WO2005113541A1 Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
12/01/2005WO2005099776A9 Steroid sparing agents and methods of using same
12/01/2005WO2005065015A3 Neutralizing antibodies and methods of use thereof
12/01/2005WO2005027831A3 Modulators of p-selectin glycoprotein ligand 1
12/01/2005WO2005011730A8 Microsome vaccine
12/01/2005WO2004094988A3 Tolerance to graft prior to thymic regeneration
12/01/2005WO2004094649A3 Tolerance to graft following thymic reactivation
12/01/2005WO2004075845A3 Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
12/01/2005US20050267304 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders
12/01/2005US20050267205 2,4-dihydroxybenzoic acid derivatives
12/01/2005US20050267190 Solid-state form of celecoxib having enhanced bioavailability
12/01/2005US20050267189 Celecoxib compositions
12/01/2005US20050267186 Minimal cardivascular and/or sedatory activity; treating pain and allodynia; selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors;
12/01/2005US20050267165 Il-8 receptor antagonists
12/01/2005US20050267163 Vanilloid receptor ligands and their use in treatments
12/01/2005US20050267137 Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof
12/01/2005US20050267133 Pyrazolopyrimidines as kinase inhibitors
12/01/2005US20050267129 Dipeptide nitrile cathepsin K inhibitors
12/01/2005US20050267114 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
12/01/2005US20050267113 Autoimmune disease; antiinflammatory agents; antiischemic agents; rheumatic diseases; antiarthritic agents; interleu
12/01/2005US20050267064 Containing unmethylated CpG dinucleotides, and an allergen; desensitization
12/01/2005US20050267057 Redirect a Th2 response to a Th1 response; treating asthma, allergies, infections, cancer immunotherapy; contain unmethylated cytosine-guanine (CpG) dinucleotides
12/01/2005US20050267022 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
12/01/2005US20050266549 Molecular switch for regulating mammalian gene expression
12/01/2005US20050266545 Lactic acid bacteria with immunoregualting activites
12/01/2005US20050266533 Therapeutic fusion protein with enhanced for use in prevention and treatment of cell proliferative, blood and nervous system disorders
12/01/2005US20050266532 Albumin fusion proteins
12/01/2005US20050266485 polynucleotides encoding a hematopoietic cytokine receptor polypeptide, for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs; test detecting a genetic disorder, cancer
12/01/2005US20050266024 Adjuvant
12/01/2005US20050266002 Methods for the treatment of cancer using anti-CD40 antibodies
12/01/2005US20050265993 Methods of treating autoimmune and inflammatory diseases
12/01/2005US20050265976 Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells
12/01/2005US20050265969 Therapeutic chemokine receptor antagonists
12/01/2005CA2566104A1 Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
12/01/2005CA2563432A1 Method for augmenting b cell depletion
12/01/2005CA2562027A1 Substituted pyrrole-2, 5-diones as protein kinase c inhibitors
12/01/2005CA2561819A1 Prodrugs of ion channel modulating compounds and uses thereof
11/2005
11/30/2005EP1600448A2 Enantiomerically pure beta-D-(-)-Dioxolane-Nucleosides
11/30/2005EP1600445A1 Medicinal composition
11/30/2005EP1600440A1 Indole derivative compounds and drugs containing the compounds as the active ingredient
11/30/2005EP1599502A1 A molecule which binds cd80 and cd86
11/30/2005EP1599482A1 Pyrazolo 1,5-a pyrimidine derivatives
11/30/2005EP1599475A2 Jnk inhibitors
11/30/2005EP1599444A1 Sulphonyl hydroxamic acid derivatives as inhibitors of s-cd23
1 ... 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 ... 1172